Tuy nhiên, bệnh nhân được tuyển dụng cho thử nghiệm này đã được rất nhiều pretreated, cho thấy rằng điều này có thể là một liệu pháp bổ sung hữu ích cho các bệnh nhân CTCL với kháng bệnh, mặc dù ảnh hưởng bất lợi. | Evidence-based Dermatology the duration of response is short. However patients recruited for this trial were heavily pretreated suggesting that this is likely to be a useful additional therapy for CTCL patients with resistant disease despite potential adverse effects. A randomised placebo-controlled trial in patients with stage IB IIB III mycosis fungoides who have undergone fewer than three previous treatments is ongoing. Ricin-labelled anti-CD5 immunoconjugate H65-RTA Efficacy A phase I trial of H65-RTA in 14 patients with resistant CTCL revealed a maximum tolerated dose of 0-33 mg kg day and PR in only four patients of short duration 3-8 months .68 Drawbacks Acute hypersensitivity effects and vascular leak syndrome were noted. Radioimmunoconjugate 90Y-T101 Efficacy A phase I trial of this radioimmunoconjugate which also targets CD5 lymphocytes in 10 patients CD5 with haematological malignancies of whom eight patients had CTCL showed PR in three CTCL patients with a median response duration of 23 Biodistribution studies showed good uptake into skin and involved lymph nodes. Drawbacks Bone-marrow suppression was observed. T cells recovered within 3 weeks but B-cell suppression persisted after 5 weeks. Comments This is an interesting phase I study because CTCL is a radiosensitive tumour. Further studies are required. What are the effects of radiotherapy in mycosis fungoides Sezary syndrome Superficial radiotherapy Efficacy No systematic reviews or RCTs were identified. Dose-response studies have clearly established that localised superficial radiotherapy is an effective palliative therapy for individual lesions in mycosis A retrospective study of palliative superficial radiotherapy used to treat 191 lesions from 20 patients with mycosis fungoides showed CRs of 95 for plaques and small 3 cm tumours and a CR of 93 for large tumours 3 cm irrespective of dose. However in-field recurrences within 1-2 years were more common for those lesions treated
